Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes

Hepatology

Volumn 31, Issue 3, 2000, Pages 769-776

  Macejak, Dennis G ^a   Jensen, Kristi L ^a   Jamison, Sharon E ^a   Domenico, Kristal ^a   Roberts, Elisabeth C ^a   Chaudhary, Nilabh ^b   Von Carlowitz, Ira ^b   Bellon, Laurent ^a   Tong, Myron J ^c   Conrad, Andrew ^d   Pavco, Pamela A ^a   Blatt, Lawrence M ^a  

^a Sirna Therapeutics Inc   (United States)

^b Atugen AG   (United States)

^c HUNTINGTON MEMORIAL HOSPITAL   (United States)

^d National Genetics Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; NUCLEASE; RIBOZYME; VIRUS RNA;

5' UNTRANSLATED REGION; ARTICLE; CHIMERA; ENZYME DEGRADATION; GENE EXPRESSION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REPORTER GENE; RNA SEQUENCE; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

EID: 17544378561     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510310331     Document Type: Article

References (19)

1. Sherlock S. Viral hepatitis. Lancet 1992;339:802.
2. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466.
3. Hoofnagle J. Hepatitis C: the clinical spectrum of disease. HEPATOLOGY 1997;26(Suppl):15S-20S.
4. Tong M, Reddy R, Lee W, Pockros PJ, Hoeffs JC, Keeffe EB, Hollinger FB, et al. Efficacy and safety of consensus interferon (CIFN) in the treatment of chronic hepatitis C: results of a multicenter phase 3 study. HEPATOLOGY 1997;26:747-754.
5. McHutchison JG, Gordon SC, Schiff ER, Schiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
6. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432.
7. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-362.
8. Houghton M, Weiner A, Han J, Kuo G, Choo Q-L. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral diseases. HEPATOLOGY 1991;14:381-388.
9. Bukh J, Purcell RH, Miller RH. Sequence analysis of the 5′ noncoding region of hepatitis C virus. Proc Natl Acad Sci U S A 1992;89:4942-4946.
10. Tsukiyama-Kohara K, Iizuka N, Kohara M, Nomoto A. Internal ribosome entry sites within hepatitis C virus RNA. J Virol 1992;66:1476-1483.
11. Wang C, Sarnow P, Siddiqui A. Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome-binding mechanism. J Virol 1993;67:3338-3344.
12. Pestova TV, Shatsky IN, Fletcher SP, Jackson RJ, Hellen CUT. A prokaryotic-like mode of cytoplasmic eukaryotic ribosome binding to the initiation codon during internal translation initiation of hepatitis C and classical swine fever virus RNAs. Genes Devel 1998;12:67-83.
13. Macejak DG, Sarnow P. Internal initiation of translation mediated by the 5′ leader of a cellular mRNA. Nature 1991;353:90-94.
14. Vagner S, Gensac MC, Maret A, Baynard F, Amalric F, Prats H, Prats AC. Alternative translation of human fibroblast growth factor 2 mRNA occurs by internal entry of ribosomes. Mol Cell Biol 1995;15:35-44.
15. Welch PJ, Yei S, Barber JR. Ribozyme gene therapy for hepatitis C virus. Clin Diag Virol 1996;10:163-171.
16. Sakamoto N, Wu CH, Wu GY. Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes. J Clin Invest 1996;98:2720-2728.
17. Lieber A, He C-Y, Polyak SJ, Gretch DR, Barr D, Kay MA. Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. J Virol 1996;70:8782-8791.
18. Jarvis TC, Wincott FE, Alby LJ, McSwiggan JA, Bëigelman L, Gustofson J, DiRenzo A, et al. Optimizing the cell efficacy of synthetic ribozymes. Site selection and chemical modifications of ribozymes targeting the proto-oncogene c-myb. J Biol Chem 1996;271:29107-29112.
19. Beigelman L, McSwiggen JA, Draper KG, Gonzalez C, Jensen K, Karpeisky AM, Modak AS, et al. Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. J Biol Chem 1995;270:25702-25708.